Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 113,322,000
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.67
  • Price/Sales 6.97
  • Price/Cash Flow 18.72
  • Price/Book 19.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.42 +7.29%
on 05/24/17
44.54 -0.22%
on 06/23/17
+2.96 (+7.14%)
since 05/23/17
3-Month
33.42 +32.97%
on 03/24/17
44.54 -0.22%
on 06/23/17
+11.29 (+34.06%)
since 03/23/17
52-Week
30.89 +43.87%
on 11/23/16
57.41 -22.59%
on 08/01/16
-8.96 (-16.78%)
since 06/23/16

Most Recent Stories

More News
Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial

Bagsvaerd, Denmark, 23 June 2017 - Novo Nordisk today announced the headline results from a 52-week double-blind phase 2 clinical trial with once-daily subcutaneous semaglutide investigating safety and...

NVO : 44.44 (+1.76%)
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

NVO : 44.44 (+1.76%)
MRK : 66.16 (+0.21%)
NVS : 86.34 (unch)
SHPG : 172.98 (-1.11%)
RHHBY : 32.7600 (+1.42%)
BMY : 56.64 (-1.20%)
NEOS : 7.25 (-2.03%)
Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza(R) based on the LEADER trial

Bagsvaerd, Denmark, 23 June 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion...

NVO : 44.44 (+1.76%)
Novo Nordisk A/S: CHMP endorses EU label update of Saxenda(R) based on the LEADER trial

Bagsvaerd, Denmark, 22 June 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under theEuropean Medicines Agency (EMA), has endorsed an update of the EU...

NVO : 44.44 (+1.76%)
Why You Should Add Novo Nordisk Stock to Your Portfolio

Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

NVO : 44.44 (+1.76%)
MRK : 66.16 (+0.21%)
LLY : 83.89 (-0.50%)
SNY : 49.33 (-0.56%)
Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion

Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk...

AZN : 35.07 (-0.82%)
NVO : 44.44 (+1.76%)
MRK : 66.16 (+0.21%)
LLY : 83.89 (-0.50%)
Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) has completed its meeting regarding the supplemental New...

NVO : 44.44 (+1.76%)
Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza(R) provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

The discussions at the Advisory Committee meeting were based on data from the LEADER trial, which involved more than 9,300 people with type 2 diabetes at high risk of major cardiovascular events.

NVO : 44.44 (+1.76%)
FDA posts briefing materials prior to Advisory Committee meeting for Victoza(R) label update

Bagsvaerd, Denmark, 16 June 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss the...

NVO : 44.44 (+1.76%)
SmarTrend Watching for Potential Rebound in Shares of Novo Nordisk After 3.02% Loss

Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $42.59 to a high of $43.09. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $43.27...

NVO : 44.44 (+1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 44.93
1st Resistance Point 44.69
Last Price 44.44
1st Support Level 44.05
2nd Support Level 43.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.